Phase I Trial of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG), a Heat Shock Protein Inhibitor, Administered Twice Weekly in Patients with Advanced Malignancies

PURPOSE: Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. EXPERIMENTAL DESIGN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Chen, Xiaohong, Figg, William D., Zajac-Kaye, Maria, Chen, Min, Steinberg, Seth M., Muir, Christine A., Yancey, Mary Ann, Horneffer, Yvonne R., Juwara, Lamin, Melillo, Giovanni, Ivy, S. Percy, Merino, Maria, Neckers, Len, Steeg, Patricia S., Conley, Barbara A., Giaccone, Giuseppe, Doroshow, James H., Murgo, Anthony J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2818572/
https://ncbi.nlm.nih.gov/pubmed/19945858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2009.10.026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados